Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SELIBORDARA phase 2 trial in relapsed or refractory multiple myeloma
2017-002326-21Phase 2Active
- Sponsor
- Fundación PETHEMA
- Start
- Feb 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor, bortezomib, dexamethasone and daratumumab in multiple myeloma (MM), sponsored by Fundación PETHEMA. Primary endpoints: Overall response rate, Clinical benefit rate and 2 more. Started Feb 2018; status: active.
02
Drugs
selinexorbortezomibdexamethasonedaratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-002326-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002326-21.